Literature DB >> 18378717

In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.

Mahtab Moayeri1, Tanisha M Robinson, Stephen H Leppla, Vladimir A Karginov.   

Abstract

We evaluated the in vivo efficacy of three beta-cyclodextrin derivatives that block the anthrax protective antigen pore. These compounds were at least 15-fold more potent than previously described beta-cyclodextrins in protecting against anthrax lethal toxin in a rat model. One of the drugs was shown to protect mice from bacterial infection.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18378717      PMCID： PMC2415786          DOI： 10.1128/AAC.00009-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.

Authors:  Yusheng Xiong; Judyann Wiltsie; Andrea Woods; Jian Guo; James V Pivnichny; Wei Tang; Alka Bansal; Richard T Cummings; Barry R Cunningham; Arthur M Friedlander; Cameron M Douglas; Scott P Salowe; Dennis M Zaller; Edward M Scolnick; Dennis M Schmatz; Kenneth Bartizal; Jeffrey D Hermes; Malcolm MacCoss; Kevin T Chapman
Journal:  Bioorg Med Chem Lett       Date:  2005-12-09       Impact factor: 2.823

3.  Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice.

Authors:  Aaron M Firoved; Georgina F Miller; Mahtab Moayeri; Rahul Kakkar; Yuequan Shen; Jason F Wiggins; Elizabeth M McNally; Wei-Jen Tang; Stephen H Leppla
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

4.  Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design.

Authors:  Vladimir A Karginov; Ekaterina M Nestorovich; Mahtab Moayeri; Stephen H Leppla; Sergey M Bezrukov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-07       Impact factor: 11.205

5.  Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.

Authors:  Johnny W Peterson; Jason E Comer; David M Noffsinger; Autumn Wenglikowski; Kristin G Walberg; Bagram M Chatuev; Ashok K Chopra; Lawrence R Stanberry; Angray S Kang; Wolfgang W Scholz; Jagadish Sircar
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Authors:  M L Pitt; S F Little; B E Ivins; P Fellows; J Barth; J Hewetson; P Gibbs; M Dertzbaugh; A M Friedlander
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

7.  Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs.

Authors:  B Ivins; P Fellows; L Pitt; J Estep; J Farchaus; A Friedlander; P Gibbs
Journal:  Vaccine       Date:  1995-12       Impact factor: 3.641

8.  Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin.

Authors:  J W Ezzell; B E Ivins; S H Leppla
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

9.  Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity.

Authors:  Mahtab Moayeri; Nathaniel W Martinez; Jason Wiggins; Howard A Young; Stephen H Leppla
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808
View more
  19 in total

Review 1.  Inhibiting bacterial toxins by channel blockage.

Authors:  Sergey M Bezrukov; Ekaterina M Nestorovich
Journal:  Pathog Dis       Date:  2015-12-09       Impact factor: 3.166

Review 2.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

Review 3.  Obstructing toxin pathways by targeted pore blockage.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Chem Rev       Date:  2012-10-11       Impact factor: 60.622

4.  Novel inhibitors of bacterial virulence: development of 5,6-dihydrobenzo[h]quinazolin-4(3H)-ones for the inhibition of group A streptococcal streptokinase expression.

Authors:  Bryan D Yestrepsky; Yuanxi Xu; Meghan E Breen; Xiaoqin Li; Walajapet G Rajeswaran; Jenny G Ryu; Roderick J Sorenson; Yasuhiro Tsume; Michael W Wilson; Wenpeng Zhang; Duxin Sun; Hongmin Sun; Scott D Larsen
Journal:  Bioorg Med Chem       Date:  2013-02-01       Impact factor: 3.641

Review 5.  Cyclodextrin derivatives as anti-infectives.

Authors:  Vladimir A Karginov
Journal:  Curr Opin Pharmacol       Date:  2013-09-04       Impact factor: 5.547

Review 6.  Multivalent Inhibitors of Channel-Forming Bacterial Toxins.

Authors:  Goli Yamini; Ekaterina M Nestorovich
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 7.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 8.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 9.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

10.  Interactions of high-affinity cationic blockers with the translocation pores of B. anthracis, C. botulinum, and C. perfringens binary toxins.

Authors:  Sergey M Bezrukov; Xian Liu; Vladimir A Karginov; Alexander N Wein; Stephen H Leppla; Michel R Popoff; Holger Barth; Ekaterina M Nestorovich
Journal:  Biophys J       Date:  2012-09-19       Impact factor: 4.033
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.